- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00082342
Transcranial Direct Current Stimulation to Treat Symptoms of Parkinson's Disease
Transcranial Direct Current Stimulation for the Treatment of Parkinson's Disease
This study will examine the effects of transcranial direct current stimulation (tDCS) on gait (walking) problems and rigidity in patients with Parkinson's disease. tDCS is a method of brain stimulation that may be able to change the electrical activity of the nerves of the brain, possibly causing Parkinson's disease symptoms to improve.
Patients between 40 and 80 years of age with moderately severe Parkinson's disease whose main symptoms are problems with walking, including freezing, or rigidity, may be eligible for this study. Candidates must be taking Sinemet or another L-DOPA drug and not have too much tremor.
Participants will be assigned to receive either real or sham (placebo) tDCS. Both groups will have eight treatments over 3-1/2 weeks. For the tDCS, electrodes are placed on wet pads on the scalp. An electrical current passes through the electrodes, travels through the scalp and skull, and causes small electrical currents in the cortex-the outer part of the brain. Participants will have a neurological examination, including an evaluation of walking, just before and just after each tDCS session. Patients' motor function will be re-evaluated at 1, 3, and 6 months after the last tDCS treatment.
...
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
Patients with PD corresponding to inclusion criteria will be recruited from the Human Motor Control Section Clinic (HMCS).
Subjects will be men and women aged 40-80 years with DOPA-responsive, akinetic-rigid PD.
Patients who have never participated in HMCS protocols for PD will be interviewed and examined by either the principal investigator or a physician from the Brain Stimulation Unit or HMCS in order to establish the diagnosis of PD and rule out any neurological condition. Only patients with a Hoehm and Yahr grade of 2 to 4 while "off" will be accepted.
Patients must be on a regimen including levodopa. The total dose of levodopa and dopamine agonists (using dopamine equivalents) has to be equal to or more than 375 milligrams per day. Other anti-parkinsonian medications are also acceptable.
Patients should have problems with walking, including freezing, so that their gait time for a 10-meter distance will be six seconds or more.
EXCLUSION CRITERIA:
Exclusion criteria are any significant medical or psychiatric illnesses (except those symptoms often associated with PD or levodopa therapy, such as sundowning and benign hallucination), pallidotomy, implanted electrodes and generator for deep brain stimulation, pregnancy.
Persons with surgically or traumatically implanted foreign bodies such as a pacemaker, implanted medical pump, implanted hearing aids, metal plate in the skull, or metal implant in the skull or eyes (other than dental appliances or fillings) that may pose a physical hazard during TEP will also be excluded. Most of these exclusions also come under the category of significant medical illness.
Patients for whom participation in the study would, in the opinion of the investigators, cause undue risk or stress for reasons such as tendency to fall, excessive fatigue, general frailty, or excessive apprehensiveness will also be excluded.
Patients unable to walk a 10-meter distance will be excluded.
Mentally impaired patients having no capacity to provide their own consent will be excluded from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: real transcranial direct current stimulation (tDCS)
|
sham stimulation
real tDCS stimulation
|
SHAM_COMPARATOR: sham transcranial direct current stimulation (tDCS)
|
sham stimulation
real tDCS stimulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gait Speed Before and After Real and Sham tDCS.
Time Frame: baseline, 1 day post, 1 month post, 3 months post-tDCS
|
Gait speed was measured by the time it took the subject to walk 10m.
Subjects were instructed to walk at a fast pace without taking the risk of falling, wearing the same shoes and using assistive devices consistently if needed.
Gait speed was measured at baseline and post-tDCS.
|
baseline, 1 day post, 1 month post, 3 months post-tDCS
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
UPDRS Total Scores Before and After Real tDCS Course and After Sham tDCS Course.
Time Frame: baseline, 1 day post, 1 month post, 3 months post-tDCS
|
The Total Unified Parkinson's Disease Rating Scale (UPDRS) is an overall clinical rating scale that quantifies the signs and symptoms of Parkinson's disease.
The total UPDRS score was obtained from subject examination, subject interviews and questionnaires.
The UPDRS encompasses measurement of mentation, behavior, mood, activities of daily living and motor skills.
The total UPDRS scores ranges from 0 (not affected) to 176 (most severely affected).
The UPDRS was administred at baseline and at 1 day post, 1 month post, and 3 months post tDCS or sham, while on medication and off medication.
|
baseline, 1 day post, 1 month post, 3 months post-tDCS
|
UPDRS Motor Scores Before and After Real tDCS Course and After Sham tDCS Course.
Time Frame: baseline, 1 day post, 1 month post, and 3 months post real and sham tDCS
|
The Motor Unified Parkinson's Disease Rating Scale (UPDRS) includes only the motor assessment of the UPDRS (Part III) and examines speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability and body bradykinesia.
The scores range from 0 (no motor impairment) to 108 (severe motor impairment).
The Motor UPDRS was administred at baseline and at 1 day post, 1 month post, and 3 months post tDCS or sham.
Subjects were assessed on medication and off medication.
|
baseline, 1 day post, 1 month post, and 3 months post real and sham tDCS
|
Bradykinesia Measure Before and After Real and Sham tDCS.
Time Frame: baseline, 1 day post, 1 month post, 3 months post tDCS
|
Bradykinesia refers to the slowness in executing a movement.
Bradykinesia was assessed by measuring the time in seconds it takes to do the following sequence, 10 times: 1) hand closing and opening while squeezing a ball 2) elbow flexion 3) hand closing and opening, and 4) elbow extension.
Subjects were allowed to practice these hand and arm movements until performance appeared not to get faster, and then were abstained from further practice to minimize learning effects.
The time it takes subjects to execute the entire sequence 10 times with either the left or right arm/hand was measured.
Means are reported for each group.
|
baseline, 1 day post, 1 month post, 3 months post tDCS
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Agnew WF, McCreery DB. Considerations for safety in the use of extracranial stimulation for motor evoked potentials. Neurosurgery. 1987 Jan;20(1):143-7. doi: 10.1097/00006123-198701000-00030.
- Antal A, Nitsche MA, Paulus W. External modulation of visual perception in humans. Neuroreport. 2001 Nov 16;12(16):3553-5. doi: 10.1097/00001756-200111160-00036.
- Braun BL. Treatment of an acute anterior disk displacement in the temporomandibular joint. A case report. Phys Ther. 1987 Aug;67(8):1234-6. doi: 10.1093/ptj/67.8.1234.
- Benninger DH, Lomarev M, Lopez G, Wassermann EM, Li X, Considine E, Hallett M. Transcranial direct current stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1105-11. doi: 10.1136/jnnp.2009.202556. Erratum In: J Neurol Neurosurg Psychiatry. 2011 Mar;82(3):354.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 030116
- 03-N-0116
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Phoressor II (IOMED)
-
New York State Psychiatric InstituteNational Alliance for Research on Schizophrenia and DepressionCompleted
-
Seoul National University Bundang HospitalCompletedNeuropathic Pain | Spinal Cord InjuryKorea, Republic of
-
Spaulding Rehabilitation HospitalTerminatedTraumatic Brain InjuryUnited States
-
Sun Pharmaceutical Industries LimitedMoebius Medical Ltd.; Nordic Bioscience Clinical Development (NBCD)CompletedOsteoarthritis of KneeUnited States, Denmark, Hong Kong
-
Sohag UniversityRecruitingNeonatal DeathEgypt
-
Guidant CorporationSuspended
-
University of California, Santa BarbaraCompleted
-
Oregon Health and Science UniversityNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease | Relationship, Marital | Caregiver Stress SyndromeUnited States
-
St. Olavs HospitalSmith & Nephew, Inc.Not yet recruitingArthroplasty | Arthritis Knee | Gait AnalysisNorway
-
Smith & Nephew, Inc.Active, not recruiting